Progyny, Inc. (NASDAQ:PGNY) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lowered its position in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 94.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 61,677 shares of the company's stock after selling 1,058,878 shares during the quarter. Thrivent Financial for Lutherans owned 0.07% of Progyny worth $1,034,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its position in shares of Progyny by 5.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 54,912 shares of the company's stock worth $2,095,000 after acquiring an additional 2,947 shares during the last quarter. Comerica Bank increased its holdings in shares of Progyny by 5.3% during the 1st quarter. Comerica Bank now owns 67,547 shares of the company's stock valued at $2,577,000 after acquiring an additional 3,428 shares during the last quarter. Cetera Advisors LLC bought a new position in shares of Progyny during the 1st quarter worth about $321,000. SG Americas Securities LLC acquired a new position in shares of Progyny in the 2nd quarter worth approximately $374,000. Finally, Cooper Financial Group bought a new position in shares of Progyny in the second quarter valued at approximately $314,000. Institutional investors and hedge funds own 94.93% of the company's stock.

Analyst Ratings Changes

PGNY has been the subject of a number of research reports. Canaccord Genuity Group cut Progyny from a "buy" rating to a "hold" rating and lowered their target price for the stock from $37.00 to $24.00 in a report on Wednesday, August 7th. Leerink Partnrs lowered Progyny from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 7th. BTIG Research downgraded shares of Progyny from a "buy" rating to a "neutral" rating in a report on Wednesday, August 7th. JMP Securities lowered shares of Progyny from an "outperform" rating to a "market perform" rating in a research report on Thursday, September 19th. Finally, Jefferies Financial Group cut their price target on shares of Progyny from $31.00 to $24.00 and set a "buy" rating for the company in a research report on Thursday, September 19th. Nine analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $25.00.

Progyny Stock Performance

NASDAQ PGNY traded down $0.74 during trading hours on Tuesday, reaching $14.85. 1,283,469 shares of the company's stock were exchanged, compared to its average volume of 1,402,026. The company's 50-day moving average is $15.79 and its two-hundred day moving average is $22.07. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of 25.60, a price-to-earnings-growth ratio of 1.80 and a beta of 1.35. Progyny, Inc. has a one year low of $13.39 and a one year high of $42.08.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.26). The business had revenue of $286.63 million during the quarter, compared to analyst estimates of $296.85 million. Progyny had a net margin of 5.03% and a return on equity of 11.36%. The business's revenue for the quarter was up 2.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.16 EPS. Research analysts predict that Progyny, Inc. will post 0.58 earnings per share for the current fiscal year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.